Insider Selling: Eli Lilly and Company (LLY) Major Shareholder Sells 200,000 Shares of Stock
Eli Lilly and Company (NYSE:LLY) major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the sale, the insider now owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Lilly Endowment Inc also recently made the following trade(s):
- On Wednesday, October 4th, Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00.
- On Friday, September 29th, Lilly Endowment Inc sold 195,000 shares of Eli Lilly and stock. The shares were sold at an average price of $85.14, for a total value of $16,602,300.00.
- On Friday, September 15th, Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock. The shares were sold at an average price of $82.53, for a total value of $15,680,700.00.
Eli Lilly and Company (NYSE LLY) traded up $1.18 during mid-day trading on Thursday, reaching $87.89. The company’s stock had a trading volume of 5,786,800 shares, compared to its average volume of 3,683,472. The firm has a market cap of $95,475.95, a P/E ratio of 21.20, a P/E/G ratio of 1.77 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Company has a fifty-two week low of $67.54 and a fifty-two week high of $89.09.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. During the same quarter in the previous year, the business earned $0.88 EPS. The company’s quarterly revenue was up 9.0% on a year-over-year basis. equities research analysts expect that Eli Lilly and Company will post 4.21 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 annualized dividend and a dividend yield of 2.56%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is currently 98.58%.
Several institutional investors have recently bought and sold shares of LLY. Acrospire Investment Management LLC lifted its position in shares of Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after buying an additional 200 shares in the last quarter. MPS Loria Financial Planners LLC bought a new position in shares of Eli Lilly and during the 2nd quarter worth approximately $128,000. San Francisco Sentry Investment Group CA bought a new position in shares of Eli Lilly and during the 2nd quarter worth approximately $129,000. Willingdon Wealth Management bought a new position in shares of Eli Lilly and during the 3rd quarter worth approximately $138,000. Finally, Wealthcare Advisory Partners LLC bought a new position in shares of Eli Lilly and during the 3rd quarter worth approximately $142,000. 76.42% of the stock is currently owned by hedge funds and other institutional investors.
Several analysts have recently commented on LLY shares. BMO Capital Markets restated a “sell” rating and issued a $73.00 target price on shares of Eli Lilly and in a research note on Wednesday, August 16th. BidaskClub downgraded Eli Lilly and from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Jefferies Group restated a “buy” rating and issued a $89.00 target price (down from $94.00) on shares of Eli Lilly and in a research note on Thursday, August 24th. Leerink Swann restated a “hold” rating on shares of Eli Lilly and in a research note on Thursday, August 31st. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $103.00 price target on shares of Eli Lilly and in a research note on Thursday, August 31st. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $90.25.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.